Vectored delivery of the ZMapp antibody cocktail (c2G4, c4G7, and c13C6) by using recombinant adeno-associated viruses (rAAVs) could be useful for preventive immunization against Ebola virus infections because rAAVs can generate long-term antibody expression. Three rAAVs (serotype 9) encoding chimeric ZMapp antibodies were produced by triple-plasmid transfection up to 10 L-scale in WAVE bioreactors using HEK293 cells grown in suspension/serum-free conditions. Efficacy of AAV-c2G4 via intravenous (i.v.), intramuscular (i.m.), and intranasal (i.n.) routes of administration was evaluated in mice with two different doses of 2.7 × 1010 and 13.0 × 1010 vector genomes (vg). The best protective efficacies after Ebola challenge were obtained with the i.v. and i.m. routes. Serum concentrations of ZMapp antibodies positively correlated with survivability. Efficacy of the rAAV-ZMapp cocktail was then evaluated at a higher dose of 30.0 × 1010 vg. It conferred a more robust protection (90% i.v. and 60% i.m.) than rAAV-c4G7 (30%) and rAAV-c13C6 (70%), both administered separately at the same dose. Delivery of rAAV-c2G4 alone achieved up to 100% protection (100% i.v. and 90% i.m.) at the same dose. In conclusion, the preventive treatment was effective in mice. However, no advantage was observed for using the rAAV-ZMapp cocktail in comparison to the utilization of the single rAAV-c2G4.
Get full access to this article
View all access options for this article.
References
1.
KaurG, SachdevaS, JhaD, et al.Ebola virus disease in the light of epidemiological triad. Trop J Med Res, 2017; 20:1.
2.
Henao-RestrepoAM, CamachoA, LonginiIM, et al.Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!). Lancet, 2017; 389:505–518.
3.
PavotV. Leading Ebola vaccine candidates. Vaccin Res, 2017; 1:1–6.
4.
DaveyRT, NordwallJ, ProschanMA. Prevail II study team. Trial of ZMapp for Ebola virus infection. N Engl J Med, 2017; 376:700–701.
5.
TradMA, NaughtonW, YeungA, et al.Ebola virus disease: an update on current prevention and management strategies. J Clin Virol, 2017; 86:5–13.
6.
QiuX, WongG, AudetJ, et al.Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature, 2014; 514:47–53.
7.
The PREVAIL II Writing Group for the M-NPIST. A randomized, controlled trial of ZMapp for Ebola virus infection. N Engl J Med, 2016; 375:1448–1456.
WatanabeN, YanoK, TsuyukiK, et al.Re-examination of regulatory opinions in Europe: possible contribution for the approval of the first gene therapy product Glybera. Mol Ther Methods Clin Dev, 2015; 2:14066.
10.
van der LooJCM, WrightJF. Progress and challenges in viral vector manufacturing. Hum Mol Genet, 2015; 2:1–11.
11.
FerreiraV, PetryH, SalmonF. Immune responses to AAV-vectors, the Glybera example from bench to bedside. Front Immunol, 2014; 5:1–15.
12.
WeleberRG, PennesiME, WilsonDJ, et al.Results at 2 years after gene therapy for RPE65-deficient leber congenital amaurosis and severe early-childhood-onset retinal dystrophy. Ophthalmology, 2016; 123:1606–1620.
13.
JacobsonSG, CideciyanAV, RatnakaramR, et al.Gene therapy for leber congenital amaurosis caused by RPE65 mutations: safety and efficacy in fifteen children and adults followed up to three years. Arch Ophthalmol, 2012; 130:9–24.
14.
BainbridgeJWB, MehatMS, SundaramV, et al.Long-term effect of gene therapy on Leber's congenital amaurosis. N Engl J Med, 2015; 372:1887–1897.
15.
MendellJR, CampbellK, Rodino-KlapacL, et al.Dystrophin immunity in Duchenne's muscular dystrophy. N Engl J Med, 2010; 363:1429–1437.
16.
RobertM-A, GilbertR, GailletB. Antibody delivery mediated by recombinant adeno-associated virus for the treatment of chronic and infectious diseases. Curr Gene Ther, 2017; 16:363–374.
17.
CroyleMA, ChengX, WilsonJM. Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther, 2001; 8:1281–1290.
18.
EtardJ-F, SowMS, LeroyS, et al.Multidisciplinary assessment of post-Ebola sequelae in Guinea (Postebogui): an observational cohort study. Lancet Infect Dis, 2017; 3099:1–8.
19.
BiavaM, CagliotiC, BordiL, et al.Detection of viral RNA in tissues following plasma clearance from an Ebola virus infected patient. PLOS Pathog, 2017; 13:e1006065.
20.
AbbateJL, MurallCL, RichnerH, et al.Potential impact of sexual transmission on Ebola virus epidemiology: Sierra Leone as a case study. PLoS Negl Trop Dis, 2016; 10:1–15.
21.
DeenGF, KnustB, BroutetN, et al.Ebola RNA persistence in semen of Ebola virus disease survivors—preliminary report. N Engl J Med, 2017; 377; 1428–1437.
22.
VarkeyJB, ShanthaJG, CrozierI, et al.Persistence of Ebola virus in ocular fluid during convalescence. N Engl J Med, 2015; 372:2423–2427.
23.
JacobsM, RodgerA, BellDJ, et al.Late Ebola virus relapse causing meningoencephalitis: a case report. Lancet, 2016; 388:498–503.
24.
BevanAK, DuqueS, FoustKD, et al.Systemic gene delivery in large species for targeting spinal cord, brain, and peripheral tissues for pediatric disorders. Mol Ther, 2011; 19:1971–1980.
25.
FoustKD, NurreE, MontgomeryCL, et al.Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat Biotechnol, 2009; 27:59–65.
26.
Benkhelifa-ZiyyatS, BesseA, RodaM, et al.Intramuscular scAAV9-SMN injection mediates widespread gene delivery to the spinal cord and decreases disease severity in SMA mice. Mol Ther, 2013; 21:282–290.
27.
MitalP, HintonBT, DufourJM. The blood–testis and blood–epididymis barriers are more than just their tight junctions. Biol Reprod, 2011; 84:851–858.
28.
ZincarelliC, SoltysS, RengoG, et al.Analysis of AAV serotypes 1–9 mediated gene expression and tropism in mice after systemic injection. Mol Ther, 2008; 16:1073–1080.
29.
PulicherlaN, ShenS, YadavS, et al.Engineering liver-detargeted AAV9 vectors for cardiac and musculoskeletal gene transfer. Mol Ther, 2011; 19:1070–1078.
30.
InagakiK, FuessS, StormTA, et al.Robust systemic transduction with AAV9 vectors in mice: efficient global cardiac gene transfer superior to that of AAV8. Mol Ther, 2006; 14:45–53.
31.
JinJF, ZhuLL, ChenM, et al.The optimal choice of medication administration route regarding intravenous, intramuscular, and subcutaneous injection. Patient Prefer Adherence, 2015; 9:923–942.
32.
LimberisMP, RacineT, KobasaD, et al.Vectored expression of the broadly neutralizing antibody FI6 in mouse airway provides partial protection against a new avian influenza a virus, H7N9. Clin Vaccine Immunol, 2013; 20:1836–1837.
33.
AdamVS, CrosariolM, KumarS, et al.Adeno-associated virus 9-mediated airway expression of antibody protects old and immunodeficient mice against influenza virus. Clin Vaccine Immunol, 2014; 21:1528–1533.
34.
LimberisMP, TretiakovaA, NambiarK, et al.Adeno-associated virus serotype 9-expressed ZMapp in mice confers protection against systemic and airway-acquired Ebola virus infection. J Infect Dis, 2016; 214:1975–1979.
35.
QiuX, FernandoL, MelitoPL, et al.Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl Trop Dis, 2012; 6:31–34.
36.
WilsonJA. Epitopes involved in antibody-mediated protection from Ebola virus. Science, 2000; 287:1664–1666.
37.
BlainM, ZengY, BendjelloulM, et al.Strong muscle-specific regulatory cassettes based on multiple copies of the human slow troponin I gene upstream enhancer. Hum Gene Ther, 2010; 21:127–134.
38.
FangJ, YiS, SimmonsA, et al.An antibody delivery system for regulated expression of therapeutic levels of monoclonal antibodies in vivo. Mol Ther, 2007; 15:1153–1159.
39.
PallesenJ, MurinCD, de ValN, et al.Structures of Ebola virus GP and sGP in complex with therapeutic antibodies. Nat Microbiol, 2016; 1:16128.
40.
GaoG, VandenbergheLH, AlviraMR, et al.Clades of adeno-associated viruses are widely disseminated in human tissues. J Virol, 2004; 78:6381–6388.
41.
ChahalPS, SchulzeE, TranR, et al.Production of adeno-associated virus (AAV) serotypes by transient transfection of HEK293 cell suspension cultures for gene delivery. J Virol Methods, 2014; 196:163–173.
42.
ChahalP, SchulzeE, BernierA, et al.292. Towards large-scale manufacturing of adeno-associated virus by transient transfection of HEK293 suspension cells in a stirred tank bioreactor using serum-free medium. Mol Ther, 2016; 24:S117–S118.
43.
CôtéJ, GarnierA, MassieB, et al.Serum-free production of recombinant proteins and adenoviral vectors by 293SF-3F6 cells. Biotechnol Bioeng, 1998; 59:567–575.
44.
ChahalPS, AucoinMG, KamenA. Primary recovery and chromatographic purification of adeno-associated virus type 2 produced by baculovirus/insect cell system. J Virol Methods, 2007; 139:61–70.
45.
GriegerJC, ChoiVW, SamulskiRJ. Production and characterization of adeno-associated viral vectors. Nat Protoc, 2006; 1:1412–1428.
46.
ZolotukhinS, ByrneB, MasonE, et al.Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther, 1999; 6:973–985.
47.
GrimmD, LeeJS, WangL, et al.In vitro and in vivo gene therapy vector evolution via multispecies interbreeding and retargeting of adeno-associated viruses. J Virol, 2008; 82:5887–5911.
48.
RussellDW, AlexanderIE, MillerAD. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors. Proc Natl Acad Sci U S A, 1995; 92:5719–5723.
49.
UmañaP, GerdesC, StoneD, et al.Efficient FLPe recombinase enables scalable production of helper-dependent adenoviral vectors with negligible helper-virus contamination. Nat Biotechnol, 2001; 19:582–585.
50.
RobertM-A, LytvynV, DeforetF, et al.Virus-like particles derived from HIV-1 for delivery of nuclear proteins: improvement of production and activity by protein engineering. Mol Biotechnol, 2016; 59:9–23.
51.
FangJ, QianJ-J, YiS, et al.Stable antibody expression at therapeutic levels using the 2A peptide. Nat Biotechnol, 2005; 23:584–590.
52.
DurocherY, PhamPL, St-LaurentG, et al.Scalable serum-free production of recombinant adeno-associated virus type 2 by transfection of 293 suspension cells. J Virol Methods, 2007; 144:32–40.
53.
LimberisMP, AdamVS, WongG, et al.Intranasal antibody gene transfer in mice and ferrets elicits broad protection against pandemic influenza. Sci Transl Med, 2013; 5:187ra72.
54.
BalazsAB, BloomJD, HongCM, et al.Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat Biotechnol, 2013; 31:647–652.
55.
HicksMJ, RosenbergJB, DeBP, et al.AAV-directed persistent expression of a gene encoding anti-nicotine antibody for smoking cessation. Sci Transl Med, 2012; 4:140ra87.
WangL, CaoO, SwalmB, et al.Major role of local immune responses in antibody formation to factor IX in AAV gene transfer. Gene Ther, 2005; 12:1453–1464.
58.
HardingFA, SticklerMM, RazoJ, et al.The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions. MAbs, 2010; 2:256–265.
59.
LuY, SongS. Distinct immune responses to transgene products from rAAV1 and rAAV8 vectors. Proc Natl Acad Sci U S A, 2009; 106:17158–17162.
60.
QiuX, AlimontiJB, MelitoPL, et al.Characterization of Zaire ebolavirus glycoprotein-specific monoclonal antibodies. Clin Immunol, 2011; 141:218–227.
61.
Rodríguez-MartínezLM, Marquez-IpiñaAR, López-PachecoF, et al.Antibody derived peptides for detection of Ebola virus glycoprotein. PLoS One, 2015; 10:e0135859.
McCartyDM, FuH, MonahanPE, et al.Adeno-associated virus terminal repeat (TR) mutant generates self-complementary vectors to overcome the rate-limiting step to transduction in vivo. Gene Ther, 2003; 10:2112–2118.
64.
FuchsSP, Martinez-NavioJM, PiatakM, et al.AAV-delivered antibody mediates significant protective effects against SIVmac239 challenge in the absence of neutralizing activity. PLoS Pathog, 2015; 11:1–20.
65.
McCartyDM, MonahanPE, SamulskiRJ. Self-complementary recombinant adeno-associated virus (scAAV) vectors promote efficient transduction independently of DNA synthesis. Gene Ther, 2001; 8:1248–1254.
66.
WangZ, MaH-I, LiJ, et al.Rapid and highly efficient transduction by double-stranded adeno-associated virus vectors in vitro and in vivo. Gene Ther, 2003; 10:2105–2111.
67.
JohnsonPR, SchneppBC, ZhangJ, et al.Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat Med, 2009; 15:901–906.
68.
HitoshiN, Ken-ichiY, Jun-ichiM. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene, 1991; 108:193–199.
69.
GubrijIB, MartinSR, PangleAK, et al.Attenuation of monocrotaline-induced pulmonary hypertension by luminal adeno-associated virus serotype 9 gene transfer of prostacyclin synthase. Hum Gene Ther, 2014; 25:498–505.
70.
WerlingNJ, SatkunanathanS, ThorpeR, et al.Systematic comparison and validation of quantitative real-time PCR methods for the quantitation of adeno-associated viral products. Hum Gene Ther Methods, 2015; 26:82–92.
71.
MaguireCA, CrommentuijnHW, MuD, et al.Mouse gender influences brain transduction by intravascularly administered AAV9. Mol Ther, 2013; 21:1470–1471.
72.
RobertM-A, ChahalPS, AudyA, et al.Manufacturing of recombinant adeno-associated viruses using mammalian expression platforms. Biotechnol J, 2017; 12.
73.
BackovicA, CervelliT, SalvettiA, et al.Capsid protein expression and adeno-associated virus like particles assembly in Saccharomyces cerevisiae. Microb Cell Fact, 2012; 11:124.
74.
ZhouX, MuzyczkaN. In vitro packaging of adeno-associated virus DNA. J Virol, 1998; 72:3241–3247.
75.
DingL, LuS, MunshiNC. In vitro packaging of an infectious recombinant adeno-associated virus 2. Gene Ther, 1997; 4:1167–1172.
76.
SteinbachS, WistubaA, BockT. Assembly of adeno-associated virus type 2 capsids in vitro. J Gen Virol, 1997; 78:1453–1462.
77.
RobertMA, LinY, BendjelloulM, et al.Strength and muscle specificity of a compact promoter derived from the slow troponin I gene in the context of episomal (gutless adenovirus) and integrating (lentiviral) vectors. J Gene Med, 2012; 14:746–760.
78.
KeckZ-Y, EnterleinSG, HowellKA, et al.Macaque monoclonal antibodies targeting novel conserved epitopes within filovirus glycoprotein. J Virol, 2015; 90:279–291.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
